Cancer News and Research

Latest Cancer News and Research

Blocking Bak inhibitors can be promising strategy in limiting resistance of cancer to TRAIL

The TRAIL ligand is a promising anticancer agent that preferentially kills tumor cells without apparent damage to healthy cells. Many cancers exhibit resistance to TRAIL, however, thus limiting its therapeutic potential.

23 Mar 2010

Short of specialists and cancer care

Associate Professor Bogda Koczwara, from the Medical Oncology Group of Australia, conducted the survey which found just 19 per cent of all those diagnosed with cancer were receiving chemotherapy.

23 Mar 2010

Can-Fite BioPharma files patent application for treatment of Uveitis with A3 adenosine receptor ligands

Can-Fite BioPharma Ltd, a biopharmaceutical company, traded on the TASE and developing anti- inflammatory and anti-cancer drugs, announced today the filing of a patent application, in conjunction with the United Stated National Institutes of Health (NIH), for the treatment of Uveitis with its A3 adenosine receptor ligands.

23 Mar 2010

CT colonography screening identifies unsuspected cancer outside of colon

A new, large-scale study of more than 10,000 adults found that more than one in every 200 asymptomatic people screened with CT colonography, or virtual colonoscopy, had clinically unsuspected malignant cancer and more than half of the cancers were located outside the colon. The findings were published in the April issue of the journal Radiology.

23 Mar 2010

Walnuts affect genes related to prostate tumor growth: Study

Walnut consumption slows the growth of prostate cancer in mice and has beneficial effects on multiple genes related to the control of tumor growth and metabolism, UC Davis and the U.S. Department of Agriculture Western Regional Research Center in Albany, Calif. have found.

23 Mar 2010

Ultraviolet portion of sunlight may play bigger role in controlling MS: Study

For more than 30 years, scientists have known that multiple sclerosis (MS) is much more common in higher latitudes than in the tropics. Because sunlight is more abundant near the equator, many researchers have wondered if the high levels of vitamin D engendered by sunlight could explain this unusual pattern of prevalence.

23 Mar 2010

New understanding of cell in immune system may guide creation of effective flu vaccines: Study

A new understanding of a certain cell in the immune system may help guide scientists in creating better flu vaccines, report researchers from the Program in Cellular and Molecular Medicine and the Immune Disease Institute at Children's Hospital Boston.

23 Mar 2010

$CTI's pixantrone trial for relapsed/refractory aggressive NHL: FDA ODAC finds data inadequate for approval$

CTI's pixantrone trial for relapsed/refractory aggressive NHL: FDA ODAC finds data inadequate for approval

Cell Therapeutics, Inc. announced today that the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee panel voted unanimously that clinical trial data was not adequate to support approval of pixantrone for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.

23 Mar 2010

Omnyx launches Global Collaborators Program to advance Digital Pathology products

Omnyx, a joint venture of GE Healthcare and The University of Pittsburgh Medical Center, today announced the launch of a Global Collaborators Program to advance Digital Pathology products, technology, and use for clinical applications.

23 Mar 2010

Nodality raises $15.5M to support launch of acute myelogenous leukemia test

Nodality, Inc., a biotechnology company focused on the development of next generation personalized medicine tests in cancer and autoimmune disease, today announced it completed financing in which the company raised $15.5 million.

23 Mar 2010

Infertile men are at greater risk for developing prostate cancer: Study

Infertile men are at nearly three times greater risk for developing clinically significant prostate cancer than the average man according to a new study published in the journal, Cancer.

23 Mar 2010

Life Beyond Cancer Foundation launches new Web site to help cancer patients

The Life Beyond Cancer Foundation, formerly known as the US Oncology Foundation, announced today that it has launched its new Web site at www.lifebeyondcancer.org. Touting an array of resources for cancer patients throughout the United States, the foundation's mission is to help cancer patients and their families connect with financial assistance, support programs and other necessary resources that can help them on their cancer journey.

23 Mar 2010

Advaxis' ADXS11-001 Phase 1 study for cervix cancer failures: 13.3% of treated patients alive at over 3 years

Ongoing follow up of the surviving patients from the phase I study of ADXS11-001 for the treatment of cervix cancer failures conducted by Advaxis, Inc.,, the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has shown that two of fifteen treated patients or 13.3% are still alive 1,248 and 1,128 days after receiving their initial dose.

23 Mar 2010

GUMC scientists awarded five-year $7.5M grant to perfect treatment of breast cancer

Scientists at the Lombardi Comprehensive Cancer Center at Georgetown University Medical Center were awarded a five-year $7.5 million grant to tease apart - in the most comprehensive way ever devised -the role of a single protein receptor in breast cells in cancer development and treatment.

22 Mar 2010

China Sky One Medical prepares for commercial launch 13 new SFDA approved products

China Sky One Medical, Inc., a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China, today announced the pending commercial launch of 13 new SFDA approved products over the next few quarters.

22 Mar 2010

Patient dosing in CyDex Pharmaceuticals' Phase 2A clinical trial of CDX-353 initiated

CyDex Pharmaceuticals, Inc. today announced the initiation of patient dosing in the company’s Phase 2A clinical trial of its Captisol-Enabled® Melphalan HCL. Melphalan is an FDA-approved chemotherapy for the palliative treatment of multiple myeloma marketed under the brand name Alkeran® by GlaxoSmithKline.

22 Mar 2010

Over one-third of people with terminal cancer do not receive entitled benefits: Study

Over one-third of people with terminal cancer are not getting the benefits to which they are entitled, a study by Macmillan Cancer Support has found.

22 Mar 2010

Rexahn Pharmaceuticals forms Parkinson’s Disease SAB to develop strategy for Serdaxin

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced the formation of its Parkinson’s Disease Scientific Advisory Board (SAB), featuring some of the leading medical researchers in neurology.

22 Mar 2010

SeeChange Health launches first health insurance company in California

SeeChange Health today launched the first new value-based health insurance company in California, offering personalized, value-based health plans that provide incentives to encourage individuals to play an active role in their health management and improve their quality of life. As the first value-based health insurance company to launch in the United States, SeeChange Health brings affordable, next-generation insurance designs to the employer group market.

22 Mar 2010

OSI Pharmaceuticals to redeem outstanding 3.25% Convertible Senior Subordinated Notes due 2023

OSI Pharmaceuticals, Inc. will fully redeem on April 21, 2010 all of its remaining outstanding 3.25% Convertible Senior Subordinated Notes due 2023 pursuant to the terms of the indenture under which the Notes were issued in September 2003. The aggregate principal amount currently outstanding of the Notes is $60,467,000. The CUSIP number for these Notes is 671040 AD 5.

22 Mar 2010

Cancer News and Research

Latest Cancer News and Research

Blocking Bak inhibitors can be promising strategy in limiting resistance of cancer to TRAIL

Short of specialists and cancer care

Can-Fite BioPharma files patent application for treatment of Uveitis with A3 adenosine receptor ligands

CT colonography screening identifies unsuspected cancer outside of colon

Walnuts affect genes related to prostate tumor growth: Study

Ultraviolet portion of sunlight may play bigger role in controlling MS: Study

New understanding of cell in immune system may guide creation of effective flu vaccines: Study

CTI's pixantrone trial for relapsed/refractory aggressive NHL: FDA ODAC finds data inadequate for approval

Omnyx launches Global Collaborators Program to advance Digital Pathology products

Nodality raises $15.5M to support launch of acute myelogenous leukemia test

Infertile men are at greater risk for developing prostate cancer: Study

Life Beyond Cancer Foundation launches new Web site to help cancer patients

Advaxis' ADXS11-001 Phase 1 study for cervix cancer failures: 13.3% of treated patients alive at over 3 years

GUMC scientists awarded five-year $7.5M grant to perfect treatment of breast cancer

China Sky One Medical prepares for commercial launch 13 new SFDA approved products

Patient dosing in CyDex Pharmaceuticals' Phase 2A clinical trial of CDX-353 initiated

Over one-third of people with terminal cancer do not receive entitled benefits: Study

Rexahn Pharmaceuticals forms Parkinson’s Disease SAB to develop strategy for Serdaxin

SeeChange Health launches first health insurance company in California

OSI Pharmaceuticals to redeem outstanding 3.25% Convertible Senior Subordinated Notes due 2023

Cancer Research - Second Edition eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Cancer News and Research

Latest Cancer News and Research

Cancer Research - Second Edition eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in